Well Lead(SH:603309) Shang Hai Zheng Quan Bao·2025-06-23 20:59Summary of Key Points Core Viewpoint The company, Guangzhou Weili Medical Instrument Co., Ltd., is participating in the establishment of an industrial investment fund named Weizhi Yihang (Suzhou) Medical Industry Investment Partnership (Limited Partnership) with a total investment of 37.5 million RMB, which represents 25% of the fund's total subscription amount of 150 million RMB. This investment aims to leverage professional investment management to align with the company's strategic development without affecting its main business operations [2][3][44]. Group 1: Investment Overview - The company has signed a partnership agreement to establish the Weizhi Yihang investment fund, with a total fundraising target of 150 million RMB [3][10]. - The company will contribute 37.5 million RMB from its own funds, which will not impact its normal business operations [3][44]. - The fund aims to invest in non-listed companies in the medical device and related sectors, focusing on those with good growth potential and core competitiveness [10][17]. Group 2: Partners and Fund Structure - The general partner of the fund is Xianglv Yilin Investment (Suzhou) Partnership (Limited Partnership), established on August 29, 2024, with a registered capital of 5 million RMB [5]. - Other limited partners include Suzhou Angel Investment Guidance Fund (Limited Partnership) and Xianglv Lianqi (Guangzhou) Venture Capital Fund Partnership (Limited Partnership), with registered capitals of 601 million RMB and 64.1 million RMB, respectively [8][9]. - The fund will have a lifespan of 10 years from the date of its first business license issuance [13]. Group 3: Investment Strategy and Management - The fund will focus on direct or indirect equity investments in non-listed enterprises within the medical industry, with a minimum of 15 projects targeted for investment [17]. - The fund's management will be handled by Xianglv Venture Capital Management (Guangzhou) Co., Ltd., which will oversee fundraising, investment decisions, and compliance with regulatory requirements [15][16]. - The fund will operate on a closed-end basis, with specific investment exit strategies outlined, including secondary market sales and direct equity transfers [21][22]. Group 4: Financial Implications and Risk Management - The investment is expected to enhance the company's strategic positioning without introducing new related transactions or competitive conflicts [44]. - The company will closely monitor the fund's operations and ensure compliance with legal and regulatory requirements [44]. - The establishment of the fund is subject to uncertainties, including the need for registration and potential challenges in fundraising [2][44].